Evidence map›Paper›PMID 42097033›Full record

ArticleRedox biology2026

DNMT1-DUOXA1 axis discovers a novel methylation-ferroptosis circuit in bicalutamide-resistant prostate cancer.

Shunyao Xia, Yan Sun, Ziwen Ye, Haixing Jia, Zan Liu, Youcheng Xiu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shunyao XiaFirst Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Electronic address: xiashunyao@hrbmu.edu.cn.
Yan SunThe Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China.
Ziwen YeFirst Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Haixing JiaDepartment of Urology, TEDA Hospital, Tianjin, China.
Zan LiuFirst Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Electronic address: Liuzan@hrbmu.edu.cn.
Youcheng XiuFirst Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China. Electronic address: xiuyoucheng0705@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer, a prevalent malignancy in the male reproductive system, poses significant therapeutic challenges due to the development of resistance to androgen deprivation therapies such as bicalutamide. While current research predominantly focuses on androgen receptor (AR)-dependent mechanisms of resistance, non-AR-dependent pathways remain poorly understood. Here, we report a novel non-AR-dependent mechanism of bicalutamide resistance centered on DUOXA1, a maturation factor for dual oxidases (DUOX) that catalyzes hydrogen peroxide (H

Indexed as

AnilidesDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationDrug Resistance, NeoplasmFerroptosisNitrilesProstatic NeoplasmsTosyl CompoundsCell Line, TumorEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansMalePromoter Regions, GeneticAnilidesbicalutamideDNA (Cytosine-5-)-Methyltransferase 1DNMT1 protein, humanNitrilesTosyl CompoundsBicalutamideDUOXA1Epigenetic modificationFerroptosisProstate cancer

Identifiers

PMID42097033
PMCPMC13156772

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.